Subscribe to our Newsletters !!
Hybridoma technology is a unique technique that ha
Bio-aerosols aren’t welcome in any laboratory. T
Belly buttons – also referred to as navels – a
Indegene, a digital-first life sciences commercial
Amidst the number of industries showing interest i
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Effective antivirals with secure clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients using COVID-19, the authors discovered that hypercoagulability according to elevated levels of D-dimers was associated with illness severity.
By calculating of a U.S. FDA approved drug library, the authors identified that an anticoagulation agent dipyridamole (DIP) at silico, which suppressed SARS-CoV-2 replication invitro.
At a proof-of-concept trial between 31 patients using COVID-19, DIP supplementation has been associated with significantly decreased concentrations of D-dimers (P<0.05), greater lymphocyte and platelet recovery in the flow, and markedly enhanced clinical outcomes for the severely ill patients compared with the control patients.
To sum up, DIP could be used for the treatment of seriously ill patients using COVID-19 through antibacterial and anticoagulation consequences.
Ascension Parish School Board
Liu, X., et al. (2020) Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Elsevier. doi.org/10.1016/j.apsb.2020.04.008.
